James Maxton MS
New York, New York, United States
604 followers
500+ connections
New York, New York, United States
604 followers
500+ connections
Activity
-
FDA approved vorasidenib (Voranigo, Servier Pharmaceuticals LLC), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2)…
FDA approved vorasidenib (Voranigo, Servier Pharmaceuticals LLC), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2)…
Liked by James Maxton MS
-
Recognizing the signs of #CushingsSyndrome can be challenging. Learn more about one person’s path to an accurate diagnosis and treatment plan…
Recognizing the signs of #CushingsSyndrome can be challenging. Learn more about one person’s path to an accurate diagnosis and treatment plan…
Liked by James Maxton MS
-
🎉 Celebrating Excellence in Clinical Research! 🎉 I am thrilled to share that I have been honored by Marquis Who's Who for my expertise in clinical…
🎉 Celebrating Excellence in Clinical Research! 🎉 I am thrilled to share that I have been honored by Marquis Who's Who for my expertise in clinical…
Liked by James Maxton MS
Education
Volunteer Experience
-
-
-
Clinical Research Associate
Einstein Healthcare Network
- 1 year 2 months
Health
Clinical Research Coordinator
Courses
-
Human Experimentation
BTC 6210
-
Human Experimentation: Methodological Issues Fundamental to Clinical Trials
-
-
Medical Device Development: A QA Regulatory Overview
-
More activity by James
-
No one is saying his name. They are making prosthetics that match skin color! And this story keeps going viral. And no one says it's John Amanam…
No one is saying his name. They are making prosthetics that match skin color! And this story keeps going viral. And no one says it's John Amanam…
Liked by James Maxton MS
-
FDA granted accelerated approval to adagrasib (Krazati; Mirati Therapeutics, Inc., a Bristol Myers Squibb company) plus cetuximab for adults with…
FDA granted accelerated approval to adagrasib (Krazati; Mirati Therapeutics, Inc., a Bristol Myers Squibb company) plus cetuximab for adults with…
Liked by James Maxton MS
-
FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma https://lnkd.in/eFhQE6qX
FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma https://lnkd.in/eFhQE6qX
Liked by James Maxton MS
-
Empowering our managers how to be consciously competent aware of workplace harassment isn’t an option but vital to the brand success.
Empowering our managers how to be consciously competent aware of workplace harassment isn’t an option but vital to the brand success.
Liked by James Maxton MS
-
🔍 Cedric Burg, Innovaderm’s COO, explores 𝘁𝗵𝗲 𝗶𝗻𝘁𝗲𝗿𝘀𝗲𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 with Applied…
🔍 Cedric Burg, Innovaderm’s COO, explores 𝘁𝗵𝗲 𝗶𝗻𝘁𝗲𝗿𝘀𝗲𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆 with Applied…
Liked by James Maxton MS
-
Innovaderm’s Founder and CEO, Dr. Robert Bissonnette, will be 𝘀𝗵𝗼𝘄𝗰𝗮𝘀𝗶𝗻𝗴 𝗱𝗲𝗿𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝘆 𝗲𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲 at the Revolutionizing…
Innovaderm’s Founder and CEO, Dr. Robert Bissonnette, will be 𝘀𝗵𝗼𝘄𝗰𝗮𝘀𝗶𝗻𝗴 𝗱𝗲𝗿𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝘆 𝗲𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲 at the Revolutionizing…
Liked by James Maxton MS
-
I’m thrilled to share that we have received FDA approval of the Evolut™ FX+ TAVR System! This is a pivotal moment for our Evolut TAVR technology, as…
I’m thrilled to share that we have received FDA approval of the Evolut™ FX+ TAVR System! This is a pivotal moment for our Evolut TAVR technology, as…
Liked by James Maxton MS
-
At Corcept, we are committed to better understanding the role cortisol plays in serious diseases. In the past year, we’ve been collaborating with…
At Corcept, we are committed to better understanding the role cortisol plays in serious diseases. In the past year, we’ve been collaborating with…
Liked by James Maxton MS
-
Delight’s first sneaker ball was amazing! Amazing night with awesome leaders!
Delight’s first sneaker ball was amazing! Amazing night with awesome leaders!
Liked by James Maxton MS
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More